Aspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery Disease

American Journal of Medicine

Volumn 120, Issue 7, 2007, Pages 631-635

  Chen, Wai Hong ^a   Cheng, Xi ^a   Lee, Pui Yin ^a   Ng, William ^a   Kwok, Jeanette Yat Yin ^a   Tse, Hung Fat ^a   Lau, Chu Pak ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aspirin; Myocardial infarction; Platelets; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; STATIN;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DEVICE; DIABETES MELLITUS; DRUG RESPONSE; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POINT OF CARE TESTING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

AGED; ASPIRIN; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34250816849     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.10.021     Document Type: Article

References (27)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
3. Helgason C.M., Bolin K.M., Hoff J.A., et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25 (1994) 2331-2336
4. Pappas J.M., Westengard J.C., and Bull B.S. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 118 (1994) 801-804
5. Gum P.A., Kottke-Marchant K., Poggio E.D., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
6. Wang J.C., Aucoin-Barry D., Manuelian D., et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92 (2003) 1492-1494
7. Patrono C., Coller B., Dalen J.E., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119 (2001) 39S-63S
8. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
9. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
10. Lee P.Y., Chen W.H., Ng W., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118 (2005) 723-727
11. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
12. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 41 (2003) 159-168
13. Feng D., McKenna C., Murillo J., et al. Effect of aspirin dosage and enteric coating on platelet reactivity. Am J Cardiol 80 (1997) 189-193
14. Karha J., Rajagopal V., Kottke-Marchant K., and Bhatt D.L. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 151 (2006) 976.e7-976.e11
15. Cox D., Maree A.O., Dooley M., et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37 (2006) 2153-2158
16. Fateh-Moghadam S., Plockinger U., Cabeza N., et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42 (2005) 99-103
17. Mehta S.S., Silver R.J., Aaronson A., et al. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97 (2006) 567-570
18. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
19. Caterina R.D., Giannessi D., Boem A., et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost 54 (1985) 528-532
20. Tohgi H., Konno S., Tamura K., et al. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 23 (1992) 1400-1403
21. Dabaghi S.F., Kamat S.G., Payne J., et al. Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. Am J Cardiol 74 (1994) 720-723
22. Hart R.G., Leonard A.D., Talbert R.L., et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy 23 (2003) 579-584
23. Dalen J.E. Aspirin to prevent heart attack and stroke: what's the right dose?. Am J Med 119 (2006) 198-202
24. Matetzky S., Shenlman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
25. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
26. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
27. Pulcinelli F.M., Pignatelli P., Celestini A., et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43 (2004) 979-984